What is the recommended dosing for Breztri (budesonide/formoterol fumarate/glycopyrrolate) in adults with asthma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Breztri Dosing

Breztri is NOT indicated for asthma—it is FDA-approved exclusively for COPD maintenance treatment. 1

FDA-Approved Dosing (COPD Only)

The recommended dose is 2 inhalations twice daily (morning and evening), delivering budesonide 320 mcg, glycopyrrolate 18 mcg, and formoterol fumarate 9.6 mcg per day (160 mcg/9 mcg/4.8 mcg per inhalation). 1

Key Administration Details:

  • Do not exceed 2 inhalations twice daily
  • Rinse mouth with water after each use (without swallowing) to reduce local corticosteroid side effects
  • Prime before first use: Release 4 sprays into the air (away from face), shaking well before each spray
  • Re-prime if: Not used for >7 days, dropped, or after weekly rinsing (2 sprays)
  • Discard when: Dose counter pointer reaches zero (red zone) 1

Critical Contraindication for Asthma

Breztri is contraindicated for asthma treatment. 1 The FDA label explicitly warns that long-acting beta2-agonists (LABAs) as monotherapy—or in combinations not specifically studied for asthma—increase the risk of asthma-related death, hospitalization, and intubation. 1

Why This Matters:

  • The triple combination of budesonide/glycopyrrolate/formoterol has not been studied in asthma patients
  • Safety and efficacy data exist only for COPD populations
  • While individual components (ICS/LABA combinations like budesonide/formoterol) are used in asthma, the addition of glycopyrrolate (a LAMA) in this specific formulation lacks asthma trial data

Alternative for Asthma Patients

If you're seeking similar therapy for asthma, consider:

Budesonide/formoterol combinations (without the LAMA component) are appropriate for asthma and can be used in SMART (Single Maintenance and Reliever Therapy) regimens for patients ≥12 years with moderate-to-severe asthma. 2, 3

  • Maintenance dosing: 1-2 inhalations twice daily (budesonide 160 mcg/formoterol 4.5 mcg per inhalation)
  • As-needed reliever: Additional inhalations for symptom relief (maximum 12 total inhalations/day in adults) 3
  • This approach reduces severe exacerbations while lowering overall ICS exposure compared to fixed-dose regimens 4

Common Pitfall:

Clinicians sometimes confuse triple therapy formulations approved for COPD with ICS/LABA combinations appropriate for asthma. Always verify the specific indication—using Breztri off-label for asthma lacks safety data and violates FDA guidance on LABA use in asthma without established ICS/LABA combination evidence. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.